Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 19/20 | 0.74 |
| ▸ | RARB | P10826 | 18/20 | 0.74 |
| ▸ | RARA | P10276 | 16/20 | 0.74 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27158809 | 0.97 | RARG (0.74) | RARGRARBRARAPTPN11 | |
| SCHEMBL27337675 | 0.95 | RARG (0.73) | RARGRARBRARA | |
| SCHEMBL27337623 | 0.93 | RARG (0.64) | RARGRARBRARA | |
| SCHEMBL27337622 | 0.90 | RARG (0.63) | RARGRARBRARA | |
| SCHEMBL27159153 | 0.89 | RARG (0.70) | RARGRARBRARAPTPN11 | |
| SCHEMBL27337620 | 0.88 | RARG (0.62) | RARGRARBRARA | |
| SCHEMBL382479 | 0.85 | RARG (1.00) | RARGRARBRARA | |
| SCHEMBL27337963 | 0.85 | RARG (0.77) | RARGRARBRARAPTPN11 | |
| SCHEMBL382692 | 0.83 | RARG (1.00) | RARGRARBRARAPTPN11 | |
| SCHEMBL382843 | 0.82 | RARG (1.00) | RARGRARBRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217992-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | Jiangxi Kerui Pharmaceutical Co., Ltd. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217992-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | Jiangxi Kerui Pharmaceutical Co., Ltd. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217992-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | Jiangxi Kerui Pharmaceutical Co., Ltd. (CN) | 2024-07-04 | — | — | US | disclosed |
| EP-4332108-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | Jiangxi Kerui Pharmaceutical Co., Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217992-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | RARA, RARG, RXRG | RARG 2/4885RARB 4/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.